Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
TDF + LNG Vaginal Ring
Product Overview
Alternative Name:
Tenofovir Disoproxil Fumarate (TDF) +Levonorgestrel Vaginal Ring
Development Status:
Active Development
Target:
Female
Mode:
Hormonal
Delivery Type:
Vaginal Ring
Duration Type:
Short-acting
Updated date:
July 12, 2016
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
levonorgestrel
,
tenofivir disoproxil fumarate (TDF)
Inactive material:
Polyurethane
Potential Multi-Purpose Technology (MPT):
Yes
Regimen:
leave in place for 30 days
Duration:
30 days
Partner:
Albert Einstein College of Medicine
,
NIAID
,
Northwestern University
Status
Project Phase:
Early Development
Project Stage:
Phase I
Status Details:
A clinical trial conducted in 2014 in New York evaluated the ring in 60 women over 14 days. The trial assessed the ring's safety and measured how much of the drug is released and the properties of the ring after use.
Programmatic Considerations
Considerations:
Other drugs could potentially be integrated into the ring to prevent other sexually transmitted infections -- a feature that could increase user rates.
The ring has a polymer construction; its elastomer swells in the presence of fluid, delivering up to 1,000 times more of the drug than current intravaginal ring technology.
Additional Information
Additional Information:
http://www.sciencedaily.com/releases/2013/09/130927123509.htm
Download Product Report
